MedTrace Logo

Triamcinolone Versus Topical Treatment in Post Operative Phacoemulsification

NCT00789971 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2008-11-13

No results posted yet for this study

Summary

Cataract extraction is one of the most common operative procedures performed throughout the world. Conventionally, patients are discharged with postoperative drops of steroids and antibiotics or a combination of both. These drops are to be administered for 2-6 weeks depending on individual eye unit protocol. Many patients find the postoperative drops arduous and non-compliance can cause prolonged inflammation and discomfort. Patients with cognitive, physical and visual impairments require assistance from family or community nurses to administer drops. A single perioperative injection of Triamcinolone has been shown to be an effective replacement for drops postoperatively in two previous studies 1, 2.

Aims \& objectives

The aim of this study is to see if a single orbital floor injection of Triamcinolone is equivalent to conventional steroid and antibiotic drops used post operatively in uneventful phacoemulsification surgery in treating postoperative inflammation.

Conditions

  • Ocular Inflammation

Interventions

DRUG

triamcinolone acetonide

40 mg of triamcinolone acetonide given inferotemporally perioperatively during phacoemulsification

DRUG

Maxitriol

one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g

Sponsors & Collaborators

  • Sligo General Hospital

    lead OTHER

Principal Investigators

  • Paul Mullaney, FRCOphth · Sligo General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-03-31
Completion
2008-04-30

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00789971 on ClinicalTrials.gov